Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Accounts Payables (2018 - 2025)

TransMedics has reported Accounts Payables over the past 8 years, most recently at $10.4 million for Q4 2025.

  • Quarterly results put Accounts Payables at $10.4 million for Q4 2025, up 0.56% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (up 0.56% YoY), and the annual figure for FY2025 was $10.4 million, up 0.56%.
  • Accounts Payables for Q4 2025 was $10.4 million at TransMedics, down from $12.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for TMDX hit a ceiling of $13.1 million in Q3 2024 and a floor of $1.3 million in Q1 2021.
  • Median Accounts Payables over the past 5 years was $8.1 million (2023), compared with a mean of $7.7 million.
  • Peak annual rise in Accounts Payables hit 451.49% in 2021, while the deepest fall reached 73.48% in 2021.
  • TransMedics' Accounts Payables stood at $6.7 million in 2021, then tumbled by 49.77% to $3.3 million in 2022, then skyrocketed by 280.63% to $12.7 million in 2023, then decreased by 19.07% to $10.3 million in 2024, then increased by 0.56% to $10.4 million in 2025.
  • The last three reported values for Accounts Payables were $10.4 million (Q4 2025), $12.2 million (Q3 2025), and $9.5 million (Q2 2025) per Business Quant data.